Pharma firms make new pledge to launch in all Euro markets at least 2 years post-authorization

As part of a drive to increase new meds across Europe, member companies of the continent’s largest pharma lobbying organization have set a new goal to seek pricing and reimbursement in all EU countries no later than 2 years after central EU marketing authorization.